Quick answer: latest quarter results, by ticker or company name

Reported Q: Q4 2024 Rev YoY: -1.5% EPS YoY: +93.2% Move: -1.05%

Elanco Animal Health Inc

5EA.DE

€20.35 -1.05%

Exchange XETRA Sector Healthcare Industry Medical Pharmaceuticals

Q4 2024

Published: Dec 31, 2024

Company Status Snapshot

Fast view of the latest quarter outcome for 5EA.DE

Reported

Report Date

Dec 31, 2024

Quarter Q4 2024

Revenue

1.02B

YoY: -1.5%

EPS

-0.02

YoY: +93.2%

Market Move

-1.05%

Previous quarter: N/A

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

Revenue of $1.02B down 1.5% year-over-year
EPS of $-0.02 increased by 93.2% from previous year
Gross margin of 50.9%
Net income of -8.00M
"N/A" - N/A

5EA.DE

Company 5EA.DE

Period Q4 2024

Currency USD

Report Type Quarterly Earnings

Generated Mar 6, 2026

Executive Summary

Elanco Animal Health reported Q4 2024 revenue of $1.02 billion, down 1.5% year over year and 1.0% quarter over quarter, reflecting a modest top-line performance in a challenging macro and competitive environment. Gross margin remained solid at ~50.9%, with EBITDA of $138 million and operating income of $88 million, delivering an operating margin of 8.6%. A net loss of $8 million, or a negative EPS of $0.0196, was driven by a large swing in total other income/expenses (-$139 million) and a pretax loss of $51 million; taxes contributed $43 million, resulting in the quarterly bottom line. Importantly, cash generation remained healthy: operating cash flow (OCF) was $177 million and free cash flow (FCF) $130 million, supporting liquidity despite the earnings shortfall.

Key Performance Indicators

Revenue

Decreasing

1.02B

QoQ: -0.97% | YoY: -1.45%

Gross Profit

Stable

519.00M

50.88% margin

QoQ: -3.53% | YoY: 0.00%

Operating Income

Decreasing

88.00M

QoQ: -31.25% | YoY: -40.14%

Net Income

Increasing

-8.00M

QoQ: -102.20% | YoY: 94.33%

EPS

Increasing

-0.02

QoQ: -102.68% | YoY: 93.24%

Revenue Trend

Margin Analysis

Financial Highlights

Key Q4 2024 metrics and notable trends:
- Revenue: $1.02B; YoY change: -1.45%; QoQ change: -0.97%.
- Gross Profit: $519M; Gross Margin: 50.88%; YoY: 0.0%; QoQ: -3.53%.
- Operating Income: $88M; Operating Margin: 8.63%; YoY: -40.14%; QoQ: -31.25%.
- EBITDA: $138M; EBITDA Margin: 13.53%.
- Net Income: -$8M; Net Margin: -0.78%; YoY: +94.33%; QoQ: -102.20%.
- EPS (GAAP): -$0.0196; Diluted EPS: -$0.0162; YoY: +93.24%; QoQ: -102.68%.
- Cash Flow: Operating cash flow $177M; Free cash flow $130M; FCF/Revenue about 12.7%; FCF-to-OCF ratio: 0.734.
- Balance Sheet: Cash $468M; Total assets $12.614B; Total debt $4.444B; Net debt $3.976B; Stockholders’ equity $6.096B; Current ratio 2.44; Quick ratio 1.248; Cash ratio 0.356.
- Leverage and profitability indicators: Debt/Equity 0.729; Debt/Capitalization 0.422; ROE -0.131% (negative); Asset turnover 0.081; DSO 71 days; DIO 282.75 days; CCC ~301 days.
- Valuation and market metrics: P/S 7.98; EV/EBITDA 87.78; P/B 1.34; P/E negative; Price to Free Cash Flow 62.59; Cash Flow per Share (OCF) $0.433; Free Cash Flow per Share $0.318.

Income Statement

Metric	Value	YoY Change	QoQ Change
Revenue	1.02B	-1.45%	-0.97%
Gross Profit	519.00M	0.00%	-3.53%
Operating Income	88.00M	-40.14%	-31.25%
Net Income	-8.00M	94.33%	-102.20%
EPS	-0.02	93.24%	-102.68%

Key Financial Ratios

Gross Profit Margin

Good

50.90%

Gross profit margin is healthy and competitive within industry standards

Operating Profit Margin

Fair

8.63%

Operating margin is moderate, room for improvement in cost management

Net Profit Margin

Weak

-0.01%

Net profit margin is below industry norms, profitability concerns

Return on Assets

Weak

0.00%

Return on assets suggests inefficient capital allocation

Return on Equity

Weak

0.00%

Return on equity suggests inefficient capital allocation

Current Ratio

Healthy

2.44

Current ratio shows adequate liquidity to meet short-term obligations

Debt to Equity

Elevated

0.73

Debt-to-equity shows significant leverage, monitor debt levels

P/E Ratio

Negative

-254.29x

Negative earnings make P/E ratio not meaningful

Price to Book

Fair Value

1.34x

Price-to-book ratio reasonable for profitable companies

Historical Earnings Comparison

Period	Revenue ($M)	EPS ($)	YoY Growth	Report
Q4 2025	1,144.00	-0.55	+12.2%	View
Q3 2025	1,137.00	-0.07	+10.4%	View
Q2 2025	1,241.00	0.02	+4.8%	View
Q1 2025	1,193.00	0.13	-1.0%	View
Q4 2024	1,020.00	-0.02	-1.5%	View

5EA.DE

Elanco Animal Health Inc

Q4 2025 Report

Elanco Animal Health Inc (5EA.DE) QQ4 2025 Results — Solid revenue growth but bottom-line pressured by non-operating items; healthy gross margins un...

Read full report

5EA.DE

Elanco Animal Health Inc

Q3 2025 Report

Elanco Animal Health Inc (5EA.DE) QQ3 2025 Results Analysis – Revenue Growth Amid Margin Pressures in Healthcare Animal Health...

Read full report

5EA.DE

Elanco Animal Health Inc

Q2 2025 Report

Elanco Animal Health Inc (5EA.DE) QQ2 2025 Earnings Analysis: Revenue Growth Amid Margin Pressure...

Read full report

5EA.DE

Elanco Animal Health Inc

Q1 2025 Report

Elanco Animal Health Inc (5EA.DE) QQ1 2025 Results – Revenue Flat, Margin Pressure and Leverage Exposure in a High-Intensity Animal Health Market...

Read full report

Elanco Animal Health Inc (5EA.DE) Q4 2024 Earnings Report

Company Status Snapshot

Earnings Highlights

Executive Summary

Key Performance Indicators

Revenue Trend

Margin Analysis

Financial Highlights

Income Statement

Key Financial Ratios

Management Insights Available for Members

Peer Comparison Available for Members

Investment Outlook & SWOT Available for Members

Historical Earnings Comparison

More 5EA.DE Quarterly Reports

5EA.DE

5EA.DE

5EA.DE

5EA.DE

Related Financial Data

Sector Analysis: Healthcare

5EA.DE Full Profile

5EA.DE Financial Statements

Earnings Calendar